摘要
目的:研究血清生长分化因子15(GDF15)水平的变化与卵巢肿瘤临床病理特征的关系及对卵巢癌疗效、预后的评估价值。方法:以84例初治卵巢癌手术患者(卵巢癌组)和81例卵巢良性疾病患者(卵巢良性疾病组)作为研究对象。采用酶联免疫吸附法分别对两组患者的血清GDF15水平进行检测。分析两组患者治疗前后血清GDF15水平变化及与卵巢癌疗效、患者无进展生存期(PFS)及总生存期(OS)的关系。结果:卵巢癌组GDF15水平高于卵巢良性疾病组。血清GDF15水平与卵巢癌患者的FIGO临床分期、淋巴结转移及病理类型有关(P<0.05)。卵巢癌患者中血清低GDF15组中完全缓解率(43.66%)高于血清高GDF15组(17.81%),差异有统计学意义(P<0.05)。Kaplan-Meier生存曲线分析显示,血清低GDF15组患者5年OS和PFS分别为79.5%和69.2%,高于血清高GDF15组患者,差异有统计学意义(均P<0.05)。COX回归提示,治疗前高的血清GDF15水平、高的FIGO分期、有淋巴结转移为影响卵巢癌患者预后的危险因素(P<0.05,OR>1)。结论:血清GDF15表达水平与卵巢癌的发生发展、疗效评估和预后有关,对卵巢癌患者的诊治具有一定的临床指导作用。
Objective:To study the relationship between serum growth differentiation factor 15(GDF15)level and the clinicopathological characteristics of ovarian tumors,and to evaluate the efficacy and prognosis of ovarian cancer.Methods:84 patients with ovarian cancer(ovarian cancer group)who had undergone initial surgery and 81 patients with benign ovarian disease(benign ovarian disease group)were selected as the study subjects.The level of serum GDF15 in the two groups was detected by enzyme-linked immunosorbent assay.The relationship between serum GDF15 level and post-treatment efficacy,progression free survival(PFS)and overall survival(OS)was analyzed.Results:The level of GDF15 in ovarian cancer group was higher than that in benign ovarian disease group.The level of serum GDF15 was correlated with FIGO clinical stage,lymph node metastasis and pathological type in patients with ovarian cancer(P<0.05).Among ovarian cancer patients,the complete remission(CR)rate was43.66%in the serum low GDF15 group,which was higher than 17.81%in the serum high GDF15 group(P<0.05).Kaplan-Meier survival analysis showed that the 5-year OS rate and PFS rate of patients in serum low GDF15 group were 79.5%and 69.2%respectively,which were higher than those of patients in serum high GDF15 group(all P<0.05).COX regression showed that high serum GDF15 level,high FIGO stage and lymph node metastasis before treatment were risk factors for prognosis of ovarian cancer patients(P<0.05,OR>1).Conclusion:The expression level of serum GDF15 is related to the occurrence,development,efficacy evaluation and prognosis prediction of ovarian cancer,which has a certain clinical guiding role in the diagnosis and treatment of ovarian cancer.
作者
蔡文灿
钱春艳
刘彦明
陈伟娟
CAI Wencan;QIAN Chunyan;LIU Yanming;CHEN Weijuan(Department of Laboratories,Yuebei People’s Hospital,Shaoguan 512026,China)
出处
《现代医学》
2020年第7期828-832,共5页
Modern Medical Journal
基金
广东省医学科研基金资助项目(2016A030313145)
关键词
卵巢癌
生长分化因子15
疗效
预后
ovarian cancer
growth differentiation factor 15
treatment efficacy
prognosis
